The market for antituberculosis drugs and vaccines: Incentives for investment in new products

Rochika G. Chaudhry, David M Bishai

Research output: Contribution to journalArticle

Abstract

The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners.

Original languageEnglish (US)
Pages (from-to)775-781
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume5
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Tuberculosis Vaccines
Motivation
Vaccines
Pharmaceutical Preparations
Prisoners
Military Personnel
Tuberculosis
HIV
Delivery of Health Care
Costs and Cost Analysis
Therapeutics
Farmers

Keywords

  • BCG
  • Directly observed therapy short course
  • DOTS
  • High-risk groups
  • Immunization
  • Market
  • TB
  • TB vaccine
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

The market for antituberculosis drugs and vaccines : Incentives for investment in new products. / Chaudhry, Rochika G.; Bishai, David M.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 5, No. 6, 12.2005, p. 775-781.

Research output: Contribution to journalArticle

@article{10c13e86cf034da29400d6b9b0056c67,
title = "The market for antituberculosis drugs and vaccines: Incentives for investment in new products",
abstract = "The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners.",
keywords = "BCG, Directly observed therapy short course, DOTS, High-risk groups, Immunization, Market, TB, TB vaccine, Tuberculosis",
author = "Chaudhry, {Rochika G.} and Bishai, {David M}",
year = "2005",
month = "12",
doi = "10.1586/14737167.5.6.775",
language = "English (US)",
volume = "5",
pages = "775--781",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - The market for antituberculosis drugs and vaccines

T2 - Incentives for investment in new products

AU - Chaudhry, Rochika G.

AU - Bishai, David M

PY - 2005/12

Y1 - 2005/12

N2 - The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners.

AB - The market for antituberculosis drugs is reviewed briefly and an estimate is formed of the potential US market for a new and improved tuberculosis vaccine. By 2010, global sales of all antituberculosis drugs are expected to reach $US612-670 million annually. An urgent need for better antituberculosis drugs exists that could permit a shorter course and less frequent dosing so that tuberculosis treatment regimens could scale up more rapidly. Should a more effective tuberculosis vaccine become available, there are approximately 18 million high-risk individuals in the USA alone for whom the vaccine would be demonstrably cost-beneficial. The high-risk groups include healthcare workers, military personnel, HIV-infected individuals, migrant farm workers and prisoners.

KW - BCG

KW - Directly observed therapy short course

KW - DOTS

KW - High-risk groups

KW - Immunization

KW - Market

KW - TB

KW - TB vaccine

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=30344484840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344484840&partnerID=8YFLogxK

U2 - 10.1586/14737167.5.6.775

DO - 10.1586/14737167.5.6.775

M3 - Article

C2 - 19807619

AN - SCOPUS:30344484840

VL - 5

SP - 775

EP - 781

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -